FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

9 letters match. Newest first.

  1. Telos Trading Limited dba Alwinshop

    FDA warns UK online seller Alwinshop that its "Prostatitis Remission Cream" is an unapproved, misbranded drug with false FDA endorsement claims.

    High risk
  2. Altru Telehealth, LLC dba Altru Telehealth

    FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.

    Low
  3. Thrivelab Co. dba Thrivelab

    FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.

    Medium
  4. Momentum Health 360 dba Momentum Health

    FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.

    Low
  5. Medica Weight Loss

    FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.

    Medium
  6. FITISH

    FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.

    Low
  7. Kin Meds

    FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.

    Low
  8. 24HrDoc, Inc. dba 24HrDoc

    FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.

    Medium
  9. Genesis Health International Inc. dba Genesis

    FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.

    Low